---
title: "Primary Prevention Long-term Registry Study in OSA and Hypertension. Survival Analysis 2010-2022"
description: "Hypertension and obstructive sleep apnea (OSA) are both common conditions that independently increase the risk cardiovascular disease including atrial fibr"
url: "https://www.clareohealth.com/clinical-trials/NCT06930989"
---

Hypertension and obstructive sleep apnea (OSA) are both common conditions that independently increase the risk cardiovascular disease including atrial fibrillation, ischemic heart disease, heart failure and stroke. OSA is also an independent promoter of hypertension development and poorly controlled hypertension is overrepresented in OSA. Finally, HT and OSA share many risk factors including obesity, and several lifestyle factors. Altogether, these links contribute to a high prevalence of patients with both disorders. The investigators suspect participants with HT and OSA are at even higher CV risk and may get their first CV event earlier in life. Comparison between HT and OSA participants vs HT alone, OSA alone or healthy controls has not previously been investigated in large studies. Thus, the investigators aim to investigate long-term risk of major cardiovascular events (MACE) or death comparing these groups in registry data between 2010-2022 in Sweden. The investigators will also investigate the protecting effect of positive airway pressure (PAP) on the OSA related CV risk increase and how many hours/night of PAP use is needed to get any protective effects.

## Key Facts

**ID:** NCT06930989
**Status:** COMPLETED
**Type:** OBSERVATIONAL
**Enrollment:** 148,467
**Sponsor:** Vastra Gotaland Region

## Detailed Description

Please see attached analysis plan

## Conditions

- Hypertension
- OSA - Obstructive Sleep Apnea
- MACE
- Survival Analysis
- PAP

## Interventions

**DEVICE: Positive airway pressure (PAP)**
Intervention as part of routine clinical care. Data from national registries.

## Eligibility

Inclusion Criteria: * Adult patients starting PAP treatment for OSA in the swedevox registry between 2010-2021 with and without hypertension.

## Who Can Participate

**Minimum age:** 18

**Sex:** ALL

**Accepts healthy volunteers:** No

## Study Locations

- Sahlgrenska University Hospital and Göteborg University, Gothenburg, VGR, Sweden

## Contact Information

## Important Dates

**Study start:** January 1, 2025

**Completion date:** April 30, 2025

**Last updated:** May 23, 2025

## Collaborators

- Swedish Heart Lung Foundation
- Göteborg University
- Lund University
- Uppsala University

[View on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06930989)
